US drugmaker Abbott (NYSE: ABT) yesterday confirmed it had reached a definitive agreement to acquire Veropharm (VRPH: RU), a leading Russian pharmaceutical manufacturer, as previously reported.
Under the terms of the deal, Abbott will acquire Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion roubles ($395 million) and 17 billion roubles (or a range of about $395 million to $495 million) depending on Garden Hills' share ownership of Veropharm at the time of close. Garden Hills currently owns more than 80% of Veropharm but is expected to own over 95% by the time the transaction closes. Under the agreement, Abbott will also assume net debt of 4.7 billion roubles.
This is the second acquisition for Abbott in a matter of weeks, the US company having agreed to buy the Chilean generic pharmaceutical firm CFR Pharmaceuticals for about $2.9 billion plus the assumption of about $430 million of debt.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze